Granzer Regulatory Consulting & Services   Report issue

For profit Phase 2
Founded: Munich Germany (2002)

Organization Overview

First Clinical Trial
2013
NCT01808638
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2018

Timeline

NOW
  • Now

Alternative names

Granzer Regulatory Consulting and Services | Granzer Regulatory Consulting & Services

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Arterial Occlusive Diseases (Phase 2)

Carcinoma, Pancreatic Ductal (Phase 2)

Epidermolysis Bullosa (Phase 2)

Epidermolysis Bullosa Dystrophica (Phase 2)

Peripheral Arterial Disease (Phase 2)

Skin Ulcer (Phase 2)

Ulcer (Phase 2)

Varicose Ulcer (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 7
  • # of Trial APIs: 8